{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059008","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.617675+00:00","generated_at":"2026-06-08T20:46:26.464967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Axsome Q3 product revenue $57.8M (up 244% YoY); Auvelity sales $37.7M","bullets":["Total Q3 product revenue was $57.8M vs $16.8M in Q3 2022; Auvelity net sales $37.7M (36% sequential growth).","Sunosi net product revenue $20.1M, up 20% YoY; total net loss of $62.2M ($1.32 per share) vs $44.8M loss in Q3 2022.","Cash and equivalents of $416.6M at Sept 30, 2023; shares outstanding 47.3M.","Pipeline on track: AXS-12 narcolepsy Phase 3 top-line expected Q1 2024; AXS-07 migraine NDA resubmission and AXS-14 fibromyalgia NDA submission both targeted H1 2024.","Auvelity sales force expanding from 162 to 260 representatives; payer coverage ~70% of covered lives."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059008","json":"https://secwatch.observer/filing/0000950170-23-059008.json","markdown":"https://secwatch.observer/filing/0000950170-23-059008.md","text":"https://secwatch.observer/filing/0000950170-23-059008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023059008/0000950170-23-059008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023059008/axsm-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T20:46:26.464967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c0a0bdd485032ef34ac79fb1596b0bf88a5fc97","claim":"Axsome Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue Total product revenue for the third quarter of 2023 was $57.8 million, net income Net loss for the third quarter of 2023 was $62.2 million, EPS $(1.32) per share.","evidence_excerpt":"Third Quarter 2023 Financial Highlights • Total product revenue for the third quarter of 2023 was $57.8 million, representing 244% year-over-year growth, and consisting of net product sales of $57.1 million and royalty revenue of $0.7 million. Total product revenue for the comparable period in 2022 was $16.8 million. • Auvelity ® net product sales were $37.7 million for the third quarter of 2023, representing a 36% sequential increase versus the second quarter of 2023. There were no Auvelity sales in the comparable 2022 period as the product was launched in October 2022. • Sunosi ® net product revenue was $20.1 million for the third quarter of 2023, representing 20% year-over-year growth, and consisting of $19.4 million in net product sales and $0.7 million in royalty revenue associated with Sunosi sales in out-licensed territories. Sunosi net product revenue for the comparable period in 2022 was $16.8 million. • Total cost of revenue was $6.5 million for the third quarter of 2023. Tot","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023059008/0000950170-23-059008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"Total product revenue for the third quarter of 2023 was $57.8 million"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $62.2 million"},{"label":"EPS","value":"$(1.32) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}